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Abstract
Psychosis increases the risk of CVD, obesity and type 2 diabetes and reduces life expectancy. There are limited data comparing the dietary habits of com-
munity-dwelling ﬁrst-episode psychosis sufferers – with autonomy over diet – and the general population. The data represent the retrospective evaluation of
nutritional data collected between 2007 and 2013 from 143 individuals from the UK population receiving treatment for ﬁrst-episode psychosis. Differences
in mean nutrient intakes between the study cohort and the national sample were tested for statistical signiﬁcance using independent t tests, incorporating
Satterthwaite’s correction where required. Mean total energy intake was lower for males (P= 0·049) and higher for females (P = 0·016) in the cohort than in
the corresponding subgroups of the national sample. Females in the study cohort consumed 12·9 (95 % CI 4·3, 21·5) g more total fat per d, whilst males
consumed 7·7 (95 % CI 0·5, 14·9) g less protein per d than the national sample. Males in the study also showed signiﬁcantly lower mean intakes than
nationally of folate, Fe, Se, vitamin D and Zn, but not vitamin C. The proportion of individuals not meeting the lower reference nutrient intakes, particu-
larly for Se (males 54·0 % and females 57·1 %) and for Fe amongst females (29·6 %), is cause for concern regarding potentially severe deﬁciencies. Further
exploration of dietary habits within ﬁrst-episode psychosis is warranted to assess whether individuals make beneﬁcial dietary changes for their physical and
mental health and wellbeing following dietary change intervention. It would also be pertinent to assess any correlation between diet and mental health
symptomology.
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Severe mental illness, such as schizophrenia, increases the risk
of CVD, obesity and type 2 diabetes and reduces life expect-
ancy(1–7). Schizophrenia is a condition characterised by
episodes of psychosis, hallmarked by an alteration of percep-
tion, thoughts, mood or behaviour(8). There are several key
factors potentially affecting the food consumption patterns
in those affected, including socio-economic status(9,10), an
illness-induced lack of motivation and a sedentary lifestyle
compared with the general population(5,11–13).
A recent systematic review reporting thirty-one pub-
lished studies on dietary patterns in schizophrenia cited
only four which related to ﬁrst-episode psychosis(14). Whilst
these(15–18) – all case–control studies – provided useful infor-
mation, it is unclear whether the study groups reported had
control over their own dietary choices. Autonomy over dietary
choice is important because acutely psychotic individuals in
the community may fail to eat meals as a consequence of
the chaos of psychotic symptoms(19), and could help deter-
mine which aspects of the diet would beneﬁt from dietary
change intervention. There are limited data comparing the
dietary habits of community-dwelling ﬁrst-episode psychosis
sufferers with the general population or with an optimum
Abbreviations: NHS, National Health Service; NME, non-milk extrinsic; RNI, reference nutrient intake.
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nutrient intake. One study(18), for example, assessed dietary
intake through recording food frequency over the previous
1 year as part of the Health and Lifestyle 2 (HAL2) question-
naire. This assessed habitual frequency, may inaccurately
reﬂect current intake, in light of recent mental health pro-
blems, particularly if the individual has a short duration of
psychosis.
Antipsychotic medication, which whilst improving sympto-
mology, is known to cause carbohydrate craving(20,21) and
hyperphagia in individuals(22–27). Animal models demonstrate
that abdominal fat deposition can occur whilst undergoing
treatment with antipsychotic medication, irrespective of a cor-
responding change in energy intake(28). This effect, found to be
reversible following the cessation of the pharmacological
agent(28), emphasises the need for robust nutritional assess-
ment and intervention in this population.
Not only are macronutrients of signiﬁcance in severe men-
tal illness, micronutrients are also essential cofactors in men-
tal function, via a potential range of mechanisms, including:
deﬁcient methylation, impaired mitochondrial function, alter-
ation of gene expression and the impaired growth and devel-
opment of neurons(29). Folate is an integral component of
methylation processes, notably the formation of neurotrans-
mitters controlling mood(30,31). Logically, therefore an
adequate folate intake must be advocated in individuals
with severe mental illness. Likewise, there is emerging evi-
dence for vitamin D as a functioning neurosteroid(32), impli-
cating it in the development and general function of brain
homeostasis. Evidence indicates that vitamin D helps reduce
Ca2+ levels in the brain, inhibits glutathione metabolism and
protects against reactive oxygen and nitrogen species(33).
Additionally, vitamin D has been speciﬁcally associated
with psychotic disorders. Individuals with schizophrenia
were found to have signiﬁcantly lower plasma levels of vita-
min D(34,35). Whilst some consider that this could be linked
to dietary habits(34), others, however, found that the diets
were not lacking in Ca-rich dairy foods(35). In addition to
these studies conducted in adult cohorts, there is evidence
of vitamin D deﬁciency associated with the prevalence of
psychotic features in adolescents(36,37). A large proportion
of vitamin D is sourced from sunlight and this could well
be lacking in those with psychosis through limited outdoor
exposure brought about from the social isolation and seden-
tary lifestyle often associated with psychosis(38). It is import-
ant thus to ensure that a baseline dietary intake is established
and then education around optimal dietary intake be provided,
where warranted.
Antioxidant systems are especially important for those with
psychosis. There is evidence that oxidative damage to neurons
has been associated with, and may therefore contribute to, the
pathophysiology of schizophrenia(39–41). Micronutrients are
involved in the production of several of the body’s antioxidant
systems. The importance of Fe, Cu and Mn has been cited as
transition metals that can cause free radical damage(42). Se is an
essential component of the glutathione peroxidase group(43).
An alteration from physiologically optimal Mn, Cu, Zn, Se
and Fe levels may play a role in the development of schizo-
phrenia and that dietary supplementation or dietary
improvement may be effective through the corresponding
increase in antioxidant activity(44).
The aim of the present paper was to begin to address the
paucity of nutritional information and present population
comparative data for key macro- and micronutrients from
community-dwelling individuals with ﬁrst-episode psychosis
from the UK population who are responsible for their own
diets.
Materials and methods
Study design and population
The primary data described represent the retrospective evalu-
ation of nutritional data collected from individuals receiving
treatment for ﬁrst-episode psychosis. These subjects are part
of the UK population, have a diagnosis of ﬁrst-episode psych-
osis and are undergoing treatment from the National Health
Service (NHS). No individuals displaying acute symptoms of
psychosis, as determined by a health professional, were offered
a nutritional assessment as this was not a health care priority
for them at that time. Individuals in the psychosis study
series, to be comparable with the national sample, were all
community-dwelling (not hospital residents) and were either
directly in control of their food purchases, or household
foods were purchased via a partner or relative, at the time
of the survey.
The cohort under study (n 143) comprises eighty-seven
males and ﬁfty-six females, who were asked by a health profes-
sional (not the nutritionist) from the Early Intervention in
Psychosis service if they would like a nutritional assessment.
All cases thus consented to, and completed, the nutritional
assessment voluntarily as part of their treatment within the
Early Intervention Service. The subjects ranged in age from
19 to 64 years. The comparative data described herein are pub-
lished data collected from a sample of the UK general popu-
lation by the Department of Health’s Food Standards Agency
(The National Diet and Nutrition Survey 2008–2011). Subject
details of this comparative study series have been described
elsewhere(45), though in summary: full datasets were compiled
on nutrient intake from 519 male and 667 female participants
aged 19–64 years, that consensually opted to take part in the
National Study.
Ethics
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing patients were approved by the NHS host institution’s
Research Governance Department. (This study did not require
ethical approval.) Verbal informed consent was obtained from
all patients relating to their participation in a nutritional assess-
ment for the purposes of their healthcare needs. Verbal con-
sent was witnessed and formally recorded in their patient
notes. The dataset was fully anonymised before statistical ana-
lysis was conducted. Individuals in the psychosis study series
were informed throughout the process that they could stop
participation in the nutritional assessment at any time, without
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the need to give any reason and without any detrimental effect
on their current or future health care. For the national sample,
written consent was obtained from all adult participants.
Dietary data collection and analysis
The same method was used to collect dietary data from the
psychosis study series and the national sample, with all
foods and beverages consumed in a food diary logged over
four consecutive days. In the psychosis study series, a
face-to-face interview was given to introduce the diary to the
participants who completed this over the subsequent 4 d.
Data from the ﬁrst-episode psychosis study series were col-
lected between 2007 and 2013, as part of routine health care
within the psychosis service, from a population of individuals
maintained on the caseloads of two Early Intervention in
Psychosis services, following their ﬁrst psychotic episode.
The food diary, once completed by the participants, was
returned to a health professional in the Early Intervention in
Psychosis Service.
Analysis of the food diaries for comparison of nutrient
proﬁle was via NetWISP dietary analysis software (Tinuviel
Software), for the psychosis study series. The key nutrients
presented in this publication include total energy, non-milk
extrinsic (NME) sugar, total fat, saturated fat, protein, carbo-
hydrate, vitamin C, vitamin D, folate, Fe, Se and Zn.
Statistical analyses
Statistical analyses of the comparison between both datasets
were carried out using SPSS for Windows v20 (SPSS Inc.).
For selected nutrients, descriptive statistics (mean, median,
standard deviation, 97·5th and 2·5th percentiles) were calcu-
lated, in line with those published for data from the
National Diet and Nutrition Survey. Differences in mean
nutrient intakes between the study series and the national sam-
ple were tested for statistical signiﬁcance using independent t
tests, incorporating Satterthwaite’s correction where required.
Micronutrient intakes in the study series were also compared
with established reference nutrient intakes (RNI) and lower
RNI developed by the Scientiﬁc Advisory Committee on
Nutrition from the 1991 Committee on Medical Aspects of
Food and Nutrition Policy report citing dietary reference
values(46).
Results
Total energy and macronutrient intake
Wide variability is evident in both groups for all intake vari-
ables. In the study series, average total energy intake is lower
for males (P= 0·049) and higher for females (P = 0·016)
than in the corresponding subgroups of the national sample
(Table 1). Males’ mean total energy intake is 646 (95 % CI
2·1, 1215) kJ less in the study series than nationally, while
for females the difference is 650·6 (95 % CI 119·7, 1181·6)
kJ more in the study series. Ta
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Amongst the macronutrients, the most notable difference is
in mean total fat intake amongst females (P = 0·004); females
in the study series consume, on average, 12·9 (95 % CI 4·3,
21·5) g more total fat per d than those in the national sample.
Indeed, at all points in the distribution, total fat consumption
appears considerably higher for females in the study series
than in the national sample. Amongst males, a lower mean
protein consumption is evident in the study series (P=
0·036); males in the study consume an average 7·7 (95 % CI
0·5, 14·9) g less protein per d than those in the national
sample.
Micronutrients
In contrast to macronutrient intake, several micronutrients
have signiﬁcantly lower reported intakes in the study group,
some markedly so, particularly amongst males.
Vitamin D intake was, on average, 2·3 µg/d in males, v. 3·1
µg/d in the general population and females consumed 1·6 v.
2·6 µg/d in the general population (Table 2). These ﬁgures
represent an intake of only 74 and 62 % of the population
intake, respectively, and there is mounting evidence that the
population does not consume sufﬁcient vitamin D(47).
Males in the study show signiﬁcantly lower mean intakes
than nationally of all the micronutrients considered, except
vitamin C. This may be consistent with their lower intakes
of protein and total energy noted previously.
Table 3 shows the numbers and percentages of individuals
in the study whose micronutrient intakes meet recognised
RNI/lower RNI and Table 4 presents the proportion of par-
ticipants with average daily intakes of vitamins and minerals
below the lower RNI. For the majority of micronutrients the
study series exhibit a higher proportion of deﬁciency than
the general population.
Discussion
The data represent the nutritional habits of those with a ﬁrst-
episode psychosis. Whilst the duration of untreated psychosis
may be variable, the dietary intake of these individuals well
represents a ﬁrst episode of psychosis study series at the base-
line of admission to services due to the validated methods
used. It is interesting to note that the total daily energy intake
in males is within recommended guidelines(46), yet is lower
than the general population(45). This could be due to missed
meals, which has previously been reported in those with
acute psychosis(19) and is within recommended guidelines(46).
Female total energy intake contrasts with the males, as
although it too is within current guidelines(46), it is higher
than the national average, as too is their fat intake. The reasons
for this are unclear and warrant further research. It is known
that stress, such as that brought on by illness, could culminate
in stress-induced emotional eating(48,49), or it could be a crav-
ing for carbohydrates as a response to commencement of anti-
psychotic medication, albeit within only a few weeks of
initiation(50). Stress has been hypothetically linked to the meta-
bolic abnormalities seen in ﬁrst-episode psychosis due to Ta
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evidence of greater stress reported throughout the early and
pre-illness phases for individuals(14).
This ﬁnding of increased total energy and carbohydrate
intake, particularly in females, within ﬁrst-episode psychosis
concurs with a previous study of those with schizophrenia(51).
When nutrient intakes of community-dwelling schizophrenic
individuals in the USA were compared with those of the
National Health and Nutrition Examination Study
(NHANES) dataset(51), total carbohydrate intake was signiﬁ-
cantly higher than that of the general population. The total
energy intake reported was again signiﬁcantly higher than
that of the general population, with the largest difference
reported in females(51). A higher fat intake and lower ﬁbre
intake relative to the general population have also been
reported from a cohort of 102 middle-aged, community-
dwelling individuals with schizophrenia(1). One study reported
a lower fat intake in the schizophrenia group, compared with
the controls(52).
Of thirty-one published studies from schizophrenic cohorts,
44 % cited an increased intake of fat; however, the differences
observed in those studies could be due to the enduring psych-
osis and potential hyperphagic effect of antipsychotic medica-
tion(20,21). Published case–control studies of ﬁrst-episode
psychosis service users have found only one macronutrient –
a higher intake of saturated fat – to be higher than that of
the general population(15), which was found to worsen post-
antipsychotic treatment for 6 months(16), whilst others found
no difference(17,18). The proportions of individuals not meet-
ing the lower RNI, particularly for Se (males 54·0 % and
females 57·1 %) and for Fe amongst females (29·6 %), is
cause for concern regarding potentially severe deﬁciencies.
In this study the suboptimal micronutrient deﬁciencies, par-
ticularly in males, are concerning because this may indicate
that whilst the diet is broadly supplying the energy needs of
the individual, the quality of food supplying that energy is sub-
standard. This could have other implications for health, par-
ticularly in light of the evidence that micronutrients may be
speciﬁcally linked to mental health.
Carbohydrate intake is higher in females, although there is
no difference between NME sugar intakes, whereas another
study has found that those with schizophrenia (not limited
to ﬁrst-episode psychosis) have a diet that is signiﬁcantly
higher in sugar(53). If this trend toward increased sugar con-
sumption being correlated to increased duration of psychosis
was to be repeated in further studies it could have implications,Ta
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Table 4. Proportion of participants with average daily intakes of vitamins
and minerals below the lower reference nutrient intake
Males Females
Study
series
(n 87) (%)
National
sample
(n 519) (%)
Study
series
(n 56) (%)
National
sample
(n 667) (%)
Vitamin C 4·6 0·6 7·1 1·2
Folate 11·5 2·1 12·5 3·3
Fe 4·6 1·5 28·6 28·8
Se 49·4 25·4 57·1 52·0
Zn 16·1 8·3 10·7 4·5
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ﬁrst, for healthcare provision, and moreover the recommenda-
tions for sugar consumption in this population subgroup. It is
also noteworthy that the study cohort’s NME sugar intake was
not signiﬁcantly higher in both sexes than the population, but
higher than the current recommendation for both males (75·5
v. 55 g/d) and females (52·1 v. 45 g/d)(46). NME sugar con-
sumption has decreased in the general population in the UK
in the last decade; the intake of the population, based upon
the 2008/2009 rolling assessment programme data, indicates
that it is still higher than recommended by the Food
Standards Agency(45). Despite this, intakes are higher than
recommended and this reinforces the suggestion that dietary
education is warranted, to help reduce sugar intake – or at
least prevent an increase – in light of links between sugar
and markers of the metabolic syndrome, and the higher preva-
lence of physical co-morbidities in those with schizophre-
nia(1–7). A high NME sugar intake was found to be
associated with type 2 diabetes in one meta-analysis(54) and
again more recently(55). When the effect of sugar consumption
is measured in terms of the glycaemic load, it has reportedly
led to an increased CHD risk(56), which was not mirrored by
the total carbohydrate intake. In a review published over a dec-
ade ago, high-sucrose diets, when consumed excessively,
increased the incidence of hypertriacylglycerolaemia in obese
individuals(57). Further convincing evidence shows that
NME sugar in sugar-sweetened beverages contributes to
weight gain and obesity(54). It is also possible that individuals
are aware of key public health advice relating to nutrition
and the association with metabolic co-morbidities, such as
type 2 diabetes and obesity. Further work in this area should
consider the measurement of the nutritional knowledge of
community-dwelling individuals with ﬁrst-episode psychosis.
The ﬁndings presented here indicate that even within 12
weeks of diagnosis with ﬁrst-episode psychosis, diets are nutri-
tionally poorer than the population. There are thus pertinent
public health issues due, ﬁrst, to the literature that links nutri-
ents to health in the general population and then moreover to
schizophrenia’s association with an increased risk of develop-
ing physical co-morbidities(15,58–61). This cannot be dissociated
from the continued disparity that exists in the life expectancy
of those with severe mental illness(2,7).
There are several potential consequences of a low micronu-
trient intake on ﬁrst-episode psychosis individuals. First, does
a potential link exists between their lack of micronutrients and
the precipitation of their mental illness? Second, could this
micronutrient-deﬁcient diet be hampering their recovery, spe-
ciﬁcally through a neurotransmission-mediated response to
prescribed medications? These processes require key nutrients,
including folate, Se and Fe, to effect these changes.
Furthermore, as the physiological requirement for vitamin D
is met through diet and the duration and intensity of the
exposure to sunlight, a chronic deﬁciency is plausible amongst
those with psychosis, due to a possible co-morbid social pho-
bia(62) and consequent lack of outdoor exposure.
As part of the nutritional education of those with ﬁrst-
episode psychosis, it is prudent to consider the nutritional
quality of daily energy sources. A plan of regular nutritional
assessments is advisable to ensure that this situation is
monitored, in light of the evidence that those with chronic
or relapsing schizophrenia have signiﬁcantly higher macronu-
trient intake compared with controls and are more likely to
develop the metabolic syndrome than the general population.
Limitations
This paper compares the mean intake of a self-selected study
series with ﬁrst-episode psychosis with the general population.
Whilst the study series may be comparable with the sample in
the National Diet and Nutrition Survey in as far as these indi-
viduals were also self-selecting, this may not be fully represen-
tative of the population’s dietary intake.
Questions may also arise over the validity of self-reported
dietary intakes in general; however, in some cases food diaries
were backed up by members of the individuals’ care networks
(partners or family members) and the concordance of total
energy intake with the general population shows that drawing
comparisons from the two datasets is valid. The generalisabil-
ity of these results is limited though because no physiological
measures, e.g. haematological or ﬁngernail samples, were taken
from the psychosis cohort to improve the validity of the par-
ticipant reporting in the food diaries and any incomplete or
inaccurate micronutrient data from the food composition
tables. This would be advantageous in any future study of
this type.
It is limiting that no information was available relating to the
socio-economic status or food purchasing patterns of the
psychosis cohort. Socio-economic status has long been linked
to food purchasing patterns, nutrient consumption(63) and
thus possibly health outcomes, yet whilst that data would
have been useful, it is important to note that psychosis can
affect any individual, irrespective of socio-economic or lifestyle
factors. Likewise, a measure of other variables that affect diet-
ary intake behaviour, such as cooking ability, inﬂuence of fam-
ily and peers and knowledge of the links between nutrition and
health(64,65) was not recorded for the psychosis cohort; how-
ever, this would warrant further investigation. Prescribed anti-
psychotic medication has also been linked to an alteration of
food intake and metabolism(20–28); thus a limitation of this
study, and one that would warrant further consideration, is
the lack of data pertaining to both the initiation and dosage
of treatment with antipsychotic medication and any effect
that may have on the dietary habits of those with psychosis.
Conclusion
Further exploration of dietary habits with ﬁrst-episode psych-
osis would be warranted to assess whether individuals make
dietary changes that would beneﬁt their physical and mental
health and wellbeing following dietary change intervention. It
would also be pertinent to assess any relationship between
diet and mental health symptomology.
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